These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 2316314

  • 1. Parlodel LAR in the treatment of macroprolactinomas.
    Kocijancic A, Prezelj J, Vrhovec I, Lancranjan I.
    Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
    [Abstract] [Full Text] [Related]

  • 2. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [Abstract] [Full Text] [Related]

  • 3. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
    Lengyel AM, Mussio W, Imamura P, Vieira JG, Lancranjan I.
    Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
    [Abstract] [Full Text] [Related]

  • 4. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A, Petrossians P, Abs R, Flandroy P, Stadnik T, de Longueville M, Lancranjan I, Stevenaert A.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M, Pagani G, Gianola D, Pagani MD, Salmoiraghi M, Ferrari L, Lancranjan I.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL, García-Luna PP, Leal-Cerro A, Cortés A, Trujillo F, Villamil F, Vaquero F, Revuelta M, Astorga R.
    Med Clin (Barc); 1994 Jun 11; 103(2):59-64. PubMed ID: 8051973
    [Abstract] [Full Text] [Related]

  • 13. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R, Jaspers C, Schulte HM, Lancranja I, Pfingsten H, Orri-Fend M, Reinwein D, Benker G.
    Clin Endocrinol (Oxf); 1993 Feb 11; 38(2):165-76. PubMed ID: 8435897
    [Abstract] [Full Text] [Related]

  • 14. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
    Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A.
    Fertil Steril; 1989 Dec 11; 52(6):930-5. PubMed ID: 2591571
    [Abstract] [Full Text] [Related]

  • 15. Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections.
    Paoletti AM, Cagnacci A, Mais V, Ajossa S, Guerriero S, Murgia C, Depau GF, Serra GG, Melis GB.
    Clin Exp Obstet Gynecol; 1994 Dec 11; 21(2):124-8. PubMed ID: 8070116
    [Abstract] [Full Text] [Related]

  • 16. [Short-term effect of delayed-action injectable bromocriptine in macroprolactinoma. French multicenter study].
    Brue T, James-Deidier A, Louvet JP, Dewailly D, Roger P, Schlienger JL, Schaison G, Hartemann P, Jaquet P.
    Ann Endocrinol (Paris); 1991 Dec 11; 52(4):273-82. PubMed ID: 1818531
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A, Bhansali A, Masoodi SR.
    Pituitary; 2005 Dec 11; 8(2):147-54. PubMed ID: 16379032
    [Abstract] [Full Text] [Related]

  • 18. Long-term treatment of macroprolactinomas with CV 205-502.
    Kvistborg A, Halse J, Bakke S, Bjøro T, Hansen E, Djøseland O, Brownell J, Jervell J.
    Acta Endocrinol (Copenh); 1993 Apr 11; 128(4):301-7. PubMed ID: 8098891
    [Abstract] [Full Text] [Related]

  • 19. Primary treatment of macroprolactinomas with Parlodel LAR.
    van 't Verlaat JW, Lancranjan I, Hendriks MJ, Croughs RJ.
    Acta Endocrinol (Copenh); 1988 Sep 11; 119(1):51-5. PubMed ID: 3414319
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ, Brownell J, Lamberts SW.
    J Clin Endocrinol Metab; 1991 May 11; 72(5):1136-41. PubMed ID: 1673685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.